Luminex Corporation (LMNX)
| Market Cap | 1.75B |
| Revenue (ttm) | 437.66M |
| Net Income (ttm) | 23.13M |
| Shares Out | 45.89M |
| EPS (ttm) | 0.50 |
| PE Ratio | 73.83 |
| Forward PE | n/a |
| Dividend | $0.38 (1.03%) |
| Ex-Dividend Date | Jun 16, 2021 |
| Volume | - |
| Open | - |
| Previous Close | 36.98 |
| Day's Range | 36.98 - 37.00 |
| 52-Week Range | 20.41 - 41.14 |
| Beta | 0.57 |
| Analysts | Hold |
| Price Target | 37.00 (+0.0%) |
| Est. Earnings Date | Aug 3, 2021 |
About LMNX
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a sof...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Luminex stock is "Hold." The 12-month stock price forecast is 37.00, which is an increase of 0.03% from the latest price.
News
Luminex Corporation Declares Second Quarter Cash Dividend
AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Luminex Corp. - LMNX
NEW YORK, April 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...
LUMINEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of P...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Luminex Corporatio...
Strength Seen in Luminex (LMNX): Can Its 12.4% Jump Turn into More Strength?
Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
INVESTIGATION ALERT: Halper Sadeh LLP Investigates LMNX, NUAN, CADE, GNMK; Shareholders are Encouraged to Contact the...
NEW YORK, April 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Luminex Corporation (NASDAQ: LMNX) concerning potent...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Luminex Corporation
NEW YORK, April 12, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Luminex Corporation (NASDAQ: LMNX) and its board of directors concerning the proposed acq...
Italian Diagnostic Developer Calls Luminex a 'Perfect Fit'
Investors reacted favorably over the announcement that Saluggia, Italy-based DiaSorin SpA (MIL:DIA) is paying $1.8 billion to purchase Austin, Texas-based Luminex Corp. (NASDAQ:LMNX), a developer of pro...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Luminex Corporation
NEW YORK, April 12, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Luminex Corporation ("Luminex" or the ...
Shareholder Alert: Ademi LLP investigates whether Luminex Corporation has obtained a Fair Price in its transaction wi...
MILWAUKEE, April 12, 2021 /PRNewswire/ -- Ademi LLP is investigating Luminex (NASDAQ: LMNX) for possible breaches of fiduciary duty and other violations of law in its transaction with DiaSorin. Click he...
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion
SALUGGIA, Italy, April 11, 2021 /PRNewswire/ -- DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement ...
Luminex Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Luminex Corporation I...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Luminex Corporation (NASDAQ: LMNX) to DiaSorin S.p.A. for $37.00 per share is fair to...
Here's Why You Should Retain Luminex (LMNX) Stock for Now
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
Luminex (LMNX) Files EUA Application for New Respiratory Assay
Luminex (LMNX) develops the combined assay to rapidly deliver clear solutions about respiratory infections from a single test.
Luminex (LMNX) Up 14.4% Since Last Earnings Report: Can It Continue?
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?
Luminex Submits Joint SARS-CoV-2 and Flu/RSV Respiratory Panel to FDA for Emergency Use Authorization
AUSTIN, Texas, March 10, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration...
Luminex Corporation to Participate at the 2021 Barclays Global Healthcare Conference
AUSTIN, Texas, March 9, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, Chairman, CEO & President, and Harriss Currie, Senior Vice President and CFO, plan to pa...
Luminex (LMNX) Surges 6.3%: Is This an Indication of Further Gains?
Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Luminex Receives FDA Emergency Use Authorization and CE Mark for Expanded NxTAG® Respiratory Panel Test Including SAR...
AUSTIN, Texas, March 4, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) fo...
Here's Why You Should Retain Luminex (LMNX) Stock for Now
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
Luminex Secures BARDA Funding To Develop And Validate Flu/COVID-19 Combo Respiratory Panel
Luminex Corporation (NASDAQ: LMNX) has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). It will support the rapid development and validation of ...
Luminex Receives BARDA Funding to Support Development and Validation of Test Combining SARS-CoV-2 and Flu/RSV Respira...
AUSTIN, Texas, Feb. 19, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received $11.3 million in funding from the Biomedical Advanced Research and Development Author...
Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat
Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.
Luminex (LMNX) Q4 Earnings Miss Estimates
Luminex (LMNX) delivered earnings and revenue surprises of -92.86% and 0.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Luminex Q4 Earnings
Shares of Luminex (NASDAQ:LMNX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 85.71% over the past year to $0.01, which missed the estimat...
Luminex Corporation Reports Fourth Quarter and Full-Year 2020 Results
AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020. All amounts in this release are in co...